Morgan Stanley cut shares of HCA Healthcare (NYSE:HCA) from an equal weight rating to an underweight rating in a report published on Wednesday, December 20th, Marketbeat.com reports. They currently have $85.00 price objective on the stock.
Several other research firms have also recently issued reports on HCA. BMO Capital Markets started coverage on HCA Healthcare in a research note on Monday, October 16th. They set an outperform rating and a $90.00 target price on the stock. Robert W. Baird dropped their price target on HCA Healthcare from $95.00 to $93.00 and set an outperform rating on the stock in a research report on Tuesday, August 22nd. ValuEngine lowered HCA Healthcare from a buy rating to a hold rating in a research report on Thursday, September 7th. Citigroup upgraded HCA Healthcare from a neutral rating to a buy rating in a research report on Tuesday, December 12th. Finally, KeyCorp reissued an overweight rating and issued a $90.00 target price (down from $95.00) on shares of HCA Healthcare in a report on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eighteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $87.80.
Shares of HCA Healthcare (NYSE HCA) traded up $2.01 during trading on Wednesday, reaching $86.97. The company’s stock had a trading volume of 1,911,085 shares, compared to its average volume of 2,114,998. The company has a quick ratio of 1.41, a current ratio of 1.68 and a debt-to-equity ratio of -6.46. The stock has a market cap of $31,270.00, a PE ratio of 12.37, a P/E/G ratio of 1.17 and a beta of 0.55. HCA Healthcare has a 1-year low of $71.18 and a 1-year high of $91.03.
HCA Healthcare (NYSE:HCA) last posted its earnings results on Tuesday, October 31st. The company reported $1.21 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.21. HCA Healthcare had a negative return on equity of 47.16% and a net margin of 6.13%. The firm had revenue of $10.70 billion for the quarter, compared to analysts’ expectations of $10.70 billion. During the same period in the previous year, the firm earned $1.45 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. sell-side analysts forecast that HCA Healthcare will post 6.56 earnings per share for the current year.
In other HCA Healthcare news, insider Michael S. Cuffe sold 2,400 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $86.63, for a total value of $207,912.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Victor L. Campbell sold 8,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $78.00, for a total value of $624,000.00. Following the completion of the sale, the senior vice president now owns 127,275 shares of the company’s stock, valued at approximately $9,927,450. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,700 shares of company stock valued at $1,773,872. 2.90% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of HCA. Northwestern Mutual Wealth Management Co. grew its position in shares of HCA Healthcare by 14.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,163 shares of the company’s stock worth $101,000 after purchasing an additional 143 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its position in shares of HCA Healthcare by 35.1% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 1,232 shares of the company’s stock worth $107,000 after purchasing an additional 320 shares in the last quarter. Atlantic Trust LLC purchased a new stake in shares of HCA Healthcare during the second quarter worth about $118,000. Acrospire Investment Management LLC grew its position in shares of HCA Healthcare by 14.3% during the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the company’s stock worth $140,000 after purchasing an additional 200 shares in the last quarter. Finally, BB&T Investment Services Inc. purchased a new stake in shares of HCA Healthcare during the second quarter worth about $141,000. Institutional investors and hedge funds own 75.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Morgan Stanley Downgrades HCA Healthcare (HCA) to Underweight” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/hca-healthcare-hca-cut-to-underweight-at-morgan-stanley.html.
HCA Healthcare Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.